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A 71-year-old man with a 13-year history of idiopathic
Parkinson’s disease (PD) was referred to us because of
severe and intractable drooling. His complaints started
4 years earlier with nocturnal drooling, but this had pro-
gressed to profuse drooling throughout the day. By that
time he also suffered from severely impaired swallowing
and severe hypokinetic dysarthria. The corners of his
mouth were persistently wet, and this had produced a
debilitating dermatitis in the perioral region, which is
illustrated in Fig. 1. At investigation we observed ery-
thematous plaques, in part sharply demarcated. The lesions
showed some rhagades and mild scaling. Moreover, despite
use of handkerchiefs, saliva was constantly dripping onto
the patient’s clothes and feet, destroying the leather of his
shoes and necessitating him to purchase new shoes every
3 months. Symptomatic treatment with anticholinergics
had been tried, but this was stopped because of systemic
side effects. Injection of botulinum toxin into the sub-
mandibular and parotid glands effectively suppressed
saliva production, and the perioral skin lesions improved
considerably.
This case history underscores that drooling can have a
tremendous impact on the quality of life of affected
patients [3]. The exact pathophysiology remains to be
determined, but is more likely related to reduced automatic
swallowing frequency than to increased production of
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Fig. 1 Prior to botulinum toxin injections into the salivary glands,
there was a marked perioral dermatitis
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DOI 10.1007/s00415-009-5144-0saliva [4]. Various symptomatic treatments are available,
aiming either to reduce saliva production (botulinum toxin,
anticholinergics, or radiotherapy over the salivary glands)
or to improve the quality and frequency of swallowing
[1, 2].
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